Shilpa Medicare soars over 11% to record high on positive phase 3 trial results for fatty liver drug NorUDCA
Shilpa Medicare shares surged over 11% after announcing successful Phase 3 trials for NorUDCA, a drug for Nonalcoholic Fatty Liver Disease (NAFLD).